A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial

AIMS: Patients with diabetes mellitus (DM) have increased platelet reactivity and reduced platelet response to clopidogrel compared with patients without DM. Prasugrel, a more potent antiplatelet agent, is associated with greater reductions in ischaemic events compared with clopidogrel, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales: Angiolillo, Dominick J., Badimon, Juan Jose, Saucedo, Jorge F., Frelinger, Andrew L., Michelson, Alan D., Jakubowski, Joseph A., Zhu, Baojin, Ojeh, Clement K., Baker, Brian A., Effron, Mark B.
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2011
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069388/
https://www.ncbi.nlm.nih.gov/pubmed/21252171
http://dx.doi.org/10.1093/eurheartj/ehq494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3069388/
https://www.ncbi.nlm.nih.gov/pubmed/21252171
http://dx.doi.org/10.1093/eurheartj/ehq494

Ejemplares similares